mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for NT5M
Gene summary
Basic gene Info.Gene symbolNT5M
Gene name5',3'-nucleotidase, mitochondrial
SynonymsdNT-2|dNT2|mdN
CytomapUCSC genome browser: 17p11.2
Type of geneprotein-coding
RefGenesNM_020201.3,
Description5' nucleotidase, mitochondrial5'(3')-deoxyribonucleotidase, mitochondrial5(3)-deoxyribonucleotidasedeoxy-5'-nucleotidase 2mitochondrial 5' nucleotidase
Modification date20141207
dbXrefs MIM : 605292
HGNC : HGNC
Ensembl : ENSG00000205309
HPRD : 12009
Vega : OTTHUMG00000059277
ProteinUniProt: Q9NPB1
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_NT5M
BioGPS: 56953
PathwayNCI Pathway Interaction Database: NT5M
KEGG: NT5M
REACTOME: NT5M
Pathway Commons: NT5M
ContextiHOP: NT5M
ligand binding site mutation search in PubMed: NT5M
UCL Cancer Institute: NT5M
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for NT5M
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
 
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
T130C129FCOAD1
W96W96CCOAD1
W96W96LLUAD1
P132P132RUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for NT5M
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
P132P132R-0.82271853
T130C129F-0.74644807
W96W96C-0.58236369
W96W96L-0.20708006
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for NT5M from PDB

Top
Differential gene expression and gene-gene network for NT5M
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of NT5M and the right PPI network was created from samples without mutations in the LBS of NT5M. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for NT5M
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for NT5M
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB02217Dpb-TSmall molecule
ExperimentalDB04672cyclic 3',5'-thymidine monophosphateSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of NT5M go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
DRM1-TRANS-(2-PHOSPHONOMETHOXYCYCLOPENTYL)URACIL1q92AP132
PO4PHOSPHATE ION1mh9AT130
PO4PHOSPHATE ION1q91AT130
U2PURIDINE-2'-PHOSPHATE1z4jAT130 P132
DGP2'-DEOXYGUANOSINE-5'-MONOPHOSPHATE1z4pXW96
D4M2',3'-DEHYDRO-2',3'-DEOXY-THYMIDINE 5'-MONOPHOSPHATE1z4qAW96
0BT1-{2-DEOXY-3,5-O-[(4-IODOPHENYL)(PHOSPHONO) METHYLIDENE]-BETA-D-THREO-PENTOFURANOSYL}-5- METHYLPYRIMIDINE-2,4(1H,3H)-DIONE4l6cAW96
2JW1-{2-DEOXY-3,5-O-[(4-NITROPHENYL)(PHOSPHONO) METHYLIDENE]-BETA-D-THREO-PENTOFURANOSYL}-5- METHYLPYRIMIDINE-2,4(1H,3H)-DIONE4nflAW96
2O21-{2-DEOXY-3,5-O-[PHENYL(PHOSPHONO)METHYLIDENE]-BETA-D- THREO-PENTOFURANOSYL}-5-[(E)-2- PHOSPHONOETHENYL]PYRIMIDINE-2,4(1H,3H)-DIONE4yikAW96
DPBDPB-T1q91AW96 P132
TMPDTMP1z4lAW96 P132
ATM3'-AZIDO-3'-DEOXYTHYMIDINE-5'-MONOPHOSPHATE2jauAW96 P132
BVPBVDU-MP2jawAW96 P132
2E21-{3,5-O-[(4-CARBOXYPHENYL)(PHOSPHONO)METHYLIDENE]-2- DEOXY-BETA-D-THREO-PENTOFURANOSYL}-5-METHYLPYRIMIDINE- 2,4(1H,3H)-DIONE4mwoAW96 P132
UMPDUMP1z4iAW96 T130 P132
T3PTHYMIDINE-3'-PHOSPHATE1z4kAW96 T130 P132
U5PUMP1z4mAW96 T130 P132


Top
Conservation information for LBS of NT5M
Multiple alignments for Q9NPB1 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas